Non Alcoholic Fatty Liver Disease Nafld Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

NAFLD describes fat accumulation in the liver of individuals who consume little or no alcohol, ranging from simple steatosis to NASH, which involves inflammation, hepatocellular injury, and progressive fibrosis that can advance to cirrhosis and hepatocellular carcinoma. The market covers pharmacologic agents targeting metabolic pathways, diagnostic testing including imaging and biomarker-based assays, and associated clinical management solutions. After decades of largely ineffective treatment options relying on lifestyle intervention alone, the approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) by the FDA in March 2024 marked a watershed moment, validating the commercial viability of NASH drug development and energizing the broader market.

• •The global NAFLD/NASH therapeutics market was valued at approximately $16.53 billion in 2025.
• •NASH, the progressive fibrotic subtype, represents the primary target for high-value pharmaceutical development.
• •Rezdiffra (resmetirom) became the first FDA-approved pharmacologic treatment for NASH with fibrosis in March 2024.

The principal engine of market expansion is the global rise in metabolic disease prevalence, with obesity and type 2 diabetes, the dominant risk factors for NAFLD, reaching epidemic proportions across both developed and emerging economies. Advances in mechanistic understanding of liver pathophysiology have unlocked new molecular targets, including peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors (FGFs), and glucagon-like peptide-1 (GLP-1) receptor pathways. Regulatory pathways have also matured, with the FDA and EMA establishing clearer clinical trial endpoints for fibrosis resolution and NASH histologic improvement, reducing development risk for sponsors.

• •Over 30 percent of adults in the United States and Western Europe are estimated to have NAFLD, with prevalence rising sharply in Asia-Pacific and Latin America.
• •GLP-1 receptor agonists from Novo Nordisk and Eli Lilly are being actively investigated for NASH indications, broadening the therapeutic pipeline.
• •Regulatory acceptance of surrogate endpoints like fibrosis regression has accelerated clinical development timelines and investor confidence.

The market is segmented by drug class, distribution channel, route of administration, and patient age group, with pharmacologic therapies representing the largest revenue segment. Drug classes under active development and commercialization include PPAR agonists, FGF21 analogs, thyroid hormone receptor-beta agonists, GLP-1 receptor agonists, and ASK1 inhibitors, each targeting distinct metabolic and fibrotic pathways. Geographically, North America commands the largest market share due to high disease prevalence, advanced healthcare infrastructure, and favorable reimbursement frameworks, while the Asia-Pacific region is emerging as the fastest-growing segment driven by surging diabetic and obese populations in China, India, and Southeast Asia.

• •North America accounts for the dominant regional share, supported by FDA-approved therapies and strong clinical trial activity.
• •Asia-Pacific is projected to experience the highest growth rates as lifestyle-related metabolic disease accelerates across populous developing nations.
• •Hospitals and specialty pharmacies constitute the primary distribution channels, with oral formulations preferred over injectable routes for patient adherence.

What are the recent trends and outlook?

The NAFLD market is positioned for sustained double-digit growth through the early 2030s as additional therapies receive regulatory approval and diagnostic screening becomes embedded in standard metabolic care protocols. Combination therapy regimens, mirroring approaches used in diabetes and cardiovascular disease, are anticipated to become the clinical standard, driving multi-drug market opportunities and companion diagnostic demand. Emerging scientific evidence increasingly frames NAFLD/NASH as a systemic metabolic disorder rather than a purely hepatic condition, expanding the range of potential prescribers and treated populations while simultaneously attracting broader pharmaceutical investment.

• •The market is projected to continue expanding at approximately 12.6 percent annually through 2031 and beyond as new drug approvals accumulate.
• •Combination therapies targeting complementary disease mechanisms are expected to dominate future treatment paradigms.
• •Greater integration of non-invasive diagnostic technologies, including elastography and blood-based biomarker panels, will broaden the treatable patient pool.